Changes in concentrations of acute phase proteins in the serum of patients might be significant in the pathogenesis of Behçet disease. This report investigates the association between ocular disease activity and serum haptoglobin levels in patients with Behçet disease, and summarizes the current understanding of the correlation between acute phase proteins and Behçet disease based on both personal studies and data from the literature.
Methods
Thirty patients with Behçet disease with ocular involvement and 15 healthy subjects were included in the study. Of the 30 patients, 14 had acute uveitis and 16 had inactive ocular involvement at the time of enrollment.
Results
There was a significant difference in haptoglobin levels between the patients with active ocular disease and controls (p=0.0005). There was also a significant difference in haptoglobin levels between the patients with inactive ocular disease and control subjects (p<0.0001). However, no significant difference was observed among patients with active versus inactive uveitis with regard to serum haptoglobin levels.
Conclusions
Higher serum haptoglobin levels in patients with Behçet disease compared to control subjects were obtained. However, elevated serum haptoglobin levels do not seem to be a risk factor for uveitis activity. Behçet disease is generally diagnosed by physical examinations and no laboratory marker has been widely accepted for follow-up of disease activity.
AdamB., CalikogluE.Serum interleukin-6, procalcitonin and C-reactive protein levels in subjects with active Behçet's disease. J Eur Dermatol Venereol2004; 18: 318–20.
RussellA.I., LawsonW.A., HaskardD.O.Potential new therapeutic options in Behçet's syndrome. BioDrugs2001; 15: 25–35.
8.
LehnerT., AdinolfiM.Acute phase proteins, C9, factor B, and lysozyme in recurrent oral ulceration and Behçet's syndrome. J Clin Pathol1980; 33: 269–75.
9.
International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet1990; 335: 1078–80.
10.
RaynesJ.G., EaglingS., McAdamK.P.Acute-phase protein synthesis in human hepatoma cells: differential regulation of serum amyloid A (SAA) and haptoglobin by interleukin-1 and interleukin-6. Clin Exp Immunol1991; 83: 488–91.
11.
MegeJ.L., DilsenN., SanguedolceV.Overproduction of monocyte derived TNF, Interleukin (IL) 6, IL 8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol1993; 20: 1544–9.
12.
AkdenizN., EsrefogluM., KelesM.S., KarakuzuA., AtasoyM.Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behcet's disease. Ann Acad Med Singapore2004; 33: 596–9.
13.
ErkiliçK., EverekliogluC., CekmenM., OzkirisA., DuyguluF., DoganH.Adenosine deaminase enzyme activity is increased and negatively correlates with catalase, superoxide dismutase and glutathione peroxidase in patients with Behçet's disease: original contributions/clinical and laboratory investigations. Mediators Inflamm2003; 12: 107–16.
14.
TuranB., GallatiH., ErdiH., GurlerA., MichelB.A., VilligerP.M.Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behçet's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol1997; 24: 128–32.
15.
KatsantonisJ., AdlerY., OrfanosC.E., ZouboulisC.C.Adamanti-ades-Behçet's disease: serum IL-8 is a more reliable marker for disease activity than C-reactive protein and erythrocyte sedimentation rate. Dermatology2000; 201: 37–9.
16.
MantasC., DireskeneliH., OzD.IL-8 producing cells in patients with Behçet's disease. Clin Exp Rheumatol2000; 18: 249–51.
17.
YamakawaY., SugitaY., NagataniT.Interleukin-6 (IL-6) in patients with Behçet's disease. J Dermatol Sci1996; 11: 189–95.
18.
SayinalpN., OzcebeO.I., OzdemirO.Cytokines in Behçet's disease. J Rheumatol1996; 23: 321–22.
19.
CidM.C., GrantD.S., HoffmanG.S., AuerbachR., FauciA.S., KleinmanH.K.Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. J Clin Invest1993; 91: 977–85.
20.
KangJ.H., KimS.K., ChoiS.Y., KwonH.Y., WonM.H.Oxidative modification of human ceruloplasmin by peroxyl radicals. Biochem Biophys Acta2001; 1568: 30–6.
21.
NateshaR.K., NateshaR., VictoryD., BarnwellS.P., HooverE.L.A prognostic role for ceruloplasmin in the diagnosis of indolent and recurrent inflammation. J Natl Med Assoc1992; 84: 781–4.
22.
KoseK., DoganP., AsciogluM., ErkilicK., AsciogluO.Oxidative stress and antioxidant defenses in plasma of patients with Behçet's disease. Tohoku J Exp Med1995; 176: 239–48.
23.
DoganP., TanrikuluG., SoyuerU., KoseK.Oxidative enzymes of polymorphonuclear leucocytes and plasma fibrinogen, ceruloplasmin, and copper levels in Behçet's disease. Clin Biochem1994; 27: 413–8.
24.
NavarroS., RicartJ.M., MedinaP.Activated protein C levels in Behçet's disease and risk of venous thrombosis. Br J Haematol2004; 126: 550–6.
25.
LehnerT., AdinolfiM.Acute phase proteins, C9, factor B, and lysozyme in recurrent oral ulceration and Behçet's syndrome. J Clin Pathol1980; 33: 269–75.
26.
AdinolfiM., LehnerT.Acute phase proteins and C9 in patients with Behçet's syndrome and aphthous ulcers. Clin Exp Immunol1976; 25: 36–9.
27.
KöseK., YaziciC., CambayN., Asciog luO., DoganP.Lipid peroxidation and erythrocyte antioxidant enzymes in patients with Behçet's disease. Tohoku J Exp Med2002; 197: 9–16.
28.
MuftuogluA.U., YaziciH., YurdakulS.Relation of serum C reactive protein and erythrocyte sedimentation rates to disease activity. Int J Dermatol1986; 25: 235–9.
29.
WakefieldD., EasterJ., BreitS.N., ClarkP., PennyR.Alpha 1 antitrypsin serum levels and phenotypes in patients with retinal vasculitis. Br J Ophthalmol1985; 69: 497–9.
30.
EverekliogluC., InalözH.S., KirtakN.Serum leptin concentration is increased in patients with Behçet's syndrome and is correlated with disease activity. Br J Dermatol2002; 147: 331–6.
NakamuraT., BoardP.G., MatsushitaK., TanakaH., MatsuyamaT., MatsudaT.Alpha 1-acid glycoprotein expression in human leukocytes: possible correlation between alpha 1-acid glycoprotein and inflammatory cytokines in rheumatoid arthritis. Inflammation1993; 17: 33–45.
33.
RicartJ.M., VayaA., TodoliJ.Haemorheological alterations in Behçet's disease are not related to a tendency for venous thrombosis. Thromb Res2005; 115: 399–404.
34.
ProbstK., FijnheerR., RothovaA.Endothelial cell activation and hypercoagulability in ocular Behçet's disease. Am J Ophthalmol2004; 137: 850–7.
35.
OzatliD., SayinalpN., BüyükasikY.Unchanged global fibrinolytic capacity despite increased factor VIIa activity in Behçet's disease: evidence of a prethrombotic state. Rheumatol Int2002; 21: 137–40.
